2024 World Conference on Lung Cancer (WCLC) - Posters-P1.09B.04 Impact of BMI on TTFields in Patients with Mnsclc: Post-hoc Analysis from the Phase 3 LUNAR Study and Simulation Model Data

P1.09B.04 Impact of BMI on TTFields in Patients with Mnsclc: Post-hoc Analysis from the Phase 3 LUNAR Study and Simulation Model Data

Back to course

Pdf Summary

The document discusses a study evaluating Tumor Treating Fields (TTFields) therapy in conjunction with immune checkpoint inhibitors (ICI) or docetaxel (DTX) for patients with metastatic non-small cell lung cancer (mNSCLC). The phase 3 LUNAR trial and subsequent post-hoc analysis aimed to assess the effect of body mass index (BMI) on the efficacy and delivery of TTFields. TTFields are non-invasive electric fields used to disrupt cancer cell processes, provided through a portable device with arrays placed on the body.<br /><br />Key findings mentioned include:<br /><br />1. **Efficacy Across BMI Subgroups**: TTFields combined with ICI/DTX showed an overall survival (OS) benefit over ICI/DTX alone, regardless of BMI. There was no significant difference in OS between patients with lower (≤25 kg/m²) and higher (>25 kg/m²) BMI.<br /><br />2. **Impact on Treatment Delivery**: Simulation data suggested TTFields could be delivered effectively across BMI categories, using different array layouts to ensure adequate field intensities in lung lobes.<br /><br />3. **Adverse Events**: Device-related adverse events (AEs) were comparable across BMI subgroups, with most AEs being mild or moderate. There were very few severe AEs, and no device-related deaths.<br /><br />4. **Clinical Benefit**: The study concludes that TTFields deliver adequate clinical benefit across various BMI ranges without significantly impacting skin AEs.<br /><br />5. **Methodology**: The study utilized computerized models to simulate TTFields delivery in healthy, overweight, and obese representations, classified by WHO criteria.<br /><br />Overall, the results suggest that TTFields therapy provides a meaningful survival advantage and is tolerably safe for mNSCLC patients, uninfluenced by BMI. The study acknowledges Novocure Inc. for backing the analyses.

Asset Subtitle

Christian Rolfo

Meta Tag

Speaker Christian Rolfo

Topic Metastatic NSCLC – Local Therapies

Keywords

Tumor Treating Fields

immune checkpoint inhibitors

docetaxel

metastatic non-small cell lung cancer

LUNAR trial

body mass index

overall survival

adverse events

clinical benefit

Novocure Inc.